Advanced delivery of biologics

Arecor for the best solution Find out more
  • Arecor for the best solution Market-Solutions/
  • Better delivery routes for liquid biological therapies Market-Solutions/hospital-home/
  • Next generation vaccines: liquid biologics without refrigeration Market-Solutions/stable-vaccines/
  • Liquid biologics for emergency use Market-Solutions/stable-liquid-formulations/
  • Market enabling solutions: labile pipeline biologics Market-Solutions/development-solutions/

About Arecor

Arecor, backed by Unilever Ventures, aims to pioneer and develop dramatically better delivery forms for proteins & biological therapies.

Find out more


  • By applying science of the highest calibre Arecor uncovers new insights in protein chemistry, enabling development of differentiating next generation biologics.

    Alan Smith, FRS CBE, Former CSO, Genzyme

  • The Arecor technology has a demonstrated potential to significantly improve the stability of complex biologicals by using novel formulation design principles.

    Bob Mattaliano, Group VP Biologics Development, Genzyme

  • Arecor’s biologic stabilisation technology provided the stabilisation breakthrough needed for commercialisation of Oxyzyme and Iodozyme, Archimed's unique wound healing products.

    Paul Davis, Chief Scientific Officer, Archimed LLP

  • We are very pleased with the work Arecor has done with our lead vaccine candidate REDEE FLU™. Providing a more effective influenza vaccine that maintains its stability is our ultimate goal at FluGen and we are indebted to the UK government and Arecor for making this possible.

    Paul Radspinner, Chief Executive Officer, Flugen

  • Arecor has transformed the development paths and delivery options for a wide range of new therapeutic products by working closely with partner companies to employ their suite of rationally-derived stabilisation technologies.

    Andy J M Richards, Biotechnology Entrepreneur and Business Angel